Treatment of acute and chronic diseases of the bronchopulmonary system that require reducing the viscosity of sputum, improving its discharge and expectoration.
Eucabal drops Storage
active substance: xylometazoline hydrochloride;
1 ml of solution contains xylometazoline hydrochloride 0.5 mg;
Excipients: benzalkonium chloride, citric acid monohydrate, sodium citrate 2H2O, glycerin 85%, purified water.
Eucabal drops Dosage form
Main physical and chemical properties: clear colorless solution with a faint odor.
Means used in diseases of the nasal cavity. Anti-edema and other drugs for topical use in diseases of the nasal cavity. Sympathomimetics, simple drugs. Code ATX R01A A07.
Xylometazoline is a sympathomimetic agent that acts on α-adrenergic receptors.
The effect of the drug begins a few minutes after application and lasts up to 12 hours. The drug causes narrowing of nasal blood vessels, reducing swelling of the nasal mucosa, its paranasal sinuses, thereby improving nasal breathing with nasal congestion and paranasal sinuses.
Eucabal drops Pharmacokinetics.
When applied topically, the drug is practically not absorbed, the concentrations of xylometazoline in blood plasma are so small that they can not be determined by modern analytical methods.
Symptomatic treatment of nasal congestion with colds, hay fever, other allergic rhinitis, sinusitis.
To facilitate the outflow of secretions in diseases of the paranasal sinuses.
As adjunctive therapy in cases of otitis media (to eliminate mucosal edema).
To facilitate rhinoscopy.
Hypersensitivity to any component of the drug; dry inflammation of the nasal mucosa (dry rhinitis), acute coronary heart disease, hyperthyroidism, angle-closure glaucoma, transphenoidal hypophysectomy and surgery with exposure of the meninges in the anamnesis. Concomitant treatment with MAO inhibitors and for
2 weeks after stopping their use.
Interaction with other medicinal products and other forms of interaction
Monoamine oxidase inhibitors (MAO inhibitors): xylometazoline may potentiate the action of monoamine oxidase inhibitors and induce hypertensive crises. Do not use xylometazoline in patients who have been taking or have been taking MAO inhibitors for the past two weeks.
Tri- and tetracyclic antidepressants: concomitant use of tri- or tetracyclic antidepressants and sympathomimetic drugs may increase the sympathomimetic effect of xylometazoline, so the simultaneous use of such drugs is not recommended.
When used in combination with β-blockers, it can cause bronchospasm or lower blood pressure.
Features of application
The drug should not be used in children under 2 years of age.
Use in children aged 2 to 11 years is recommended only under adult supervision.
The drug should not be used for more than 7 consecutive days. Prolonged or excessive use may lead to recurrence of nasal congestion and / or atrophy of the nasal mucosa.
The drug should be used with caution in patients who, when using adrenergic drugs have severe reactions, manifested as insomnia, dizziness, tremors, cardiac arrhythmia, increased blood pressure.
Patients with prolonged QT syndrome who receive xylometazoline may be at increased risk for severe ventricular arrhythmias.
Do not exceed the recommended dose, especially in the treatment of children and the elderly.
Caution should be exercised when administering to patients with cardiovascular disease, hypertension, diabetes mellitus, thyroid disease, pheochromocytoma, prostate hypertrophy, and should not be used in patients receiving concomitant treatment with 2 MA inhibitors and application. Each pack of drops should be used by only one person to avoid infection.
The drug contains benzalkonium chloride, which may cause irritation of the nasal mucosa.